Electrical Stimulation Releases Opiate-Like Substance in Pain, Migraine Patients

Application of electricity through transcranial direct current stimulation (tDCS) to certain regions of the brain of a patient with trigeminal neuralgia, a condition involving severe facial pain, has been shown to release an opiate-like substance called mu-opioid. This is the same substance targeted by many pain medications, including morphine, and is considered one of the body's most powerful painkillers.

This case study builds on earlier research initially conducted on chronic migraine patients, making it highly relevant to many members of our Migraine.com community, myself included, as well as those who live with trigeminal neuralgia in addition to migraine disease.


tDCS is an extremely mild electrical current. To help put it in perspective, note that electroconvulsive therapy (ECT), which is used to treat resistant psychiatric disorders, applies between 200 and 1600 milliamperes. tDCS applies just 2 milliamperes.

Electrodes were applied to the study participant's head and her skull was electrically stimulated using tDCS for 20 minutes during a PET scan. A radiotracer able to reach the areas of the brain affected by trigeminal neuralgia was used to measure the brain's release of mu-opioid.

The researchers determined that multiple sessions of tDCS are necessary to create the release of the opiate-like chemical. A single application of tDCS actually decreased the patient's ability to tolerate the pain of trigeminal neuralgia.

A crucial limitation of this research is the fact that only one patient was included in the study. If this research holds up in larger studies, it could not only provide an additional option for patients dealing with conditions like trigeminal neuralgia, chronic migraine and fibromyalgia, but also reduce the need for these patients to use pain killing medications, which can be fraught with complications when used long term.

By providing your email address, you are agreeing to our privacy policy. We never sell or share your email address.

More on this topic

This article represents the opinions, thoughts, and experiences of the author; none of this content has been paid for by any advertiser. The Migraine.com team does not recommend or endorse any products or treatments discussed herein. Learn more about how we maintain editorial integrity here.

Join the conversation

or create an account to comment.
poll graphic

Community Poll

Do you prefer reading stories from others with migraine or informational content on our site?